BCI
TVTX icon

Brinker Capital Investments’s Travere Therapeutics TVTX Stock Holding History

Brinker Capital Investments’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$530K Sell
17,850
-744
-4% -$22.2K ﹤0.01% 1423
2025
Q4 		$710K Buy
+18,594
New +$605K 0.01% 1427

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Brinker Capital Investments's TVTX Position: Q1 2026 in Review

Brinker Capital Investments reduced its Travere Therapeutics (TVTX) stake by 4% in Q1 2026, selling an estimated $22.2K and leaving 17,850 shares worth $530K. The position accounts for ﹤0.01% of the portfolio, ranked #1423.

Brinker Capital Investments first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $710K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Brinker Capital Investments held 17,850 shares of Travere Therapeutics worth $530K as of Q1 2026.
  • Brinker Capital Investments sold 744 Travere Therapeutics shares in Q1 2026, an estimated $22.2K.
  • Travere Therapeutics made up ﹤0.01% of Brinker Capital Investments's portfolio in Q1 2026, its #1423 holding.
  • Brinker Capital Investments first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Brinker Capital Investments's Travere Therapeutics position peaked at $710K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.